In autoimmune diseases and transplant rejection, MSCs suppress pathogenic CD8+ T cell activation by transferring mitochondria, resulting in diminished T cell proliferation, IFN‐γ production, and reduced diabetogenic potential. The gene discussed is CD8A; the disease is autoimmune disease.